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Abstract
Objective: Increasing magnesium intake might reduce the risk of cardiovascular 
disease (CVD). Whether potential effects on cortisol contribute to these beneficial 
effects on cardiovascular health remains unclear. We therefore studied effects of 
long-term oral magnesium supplementation on glucocorticoid metabolism, specifi-
cally on the excretion of urinary cortisol, cortisone and their metabolites, as well as 
on the ratios reflecting enzymatic activity of 11β-hydroxysteroid dehydrogenases 
(11β-HSDs) and A-ring reductases.
Design: A post-hoc analysis of a randomized trial with allocation to a magnesium sup-
plement (350 mg/day) or a placebo for 24-week.
Patients: Forty-nine overweight men and women, aged between 45 and 70 years.
Measurements: Cortisol, cortisone and their metabolites (tetrahydrocortisol [THF], 
allo-tetrahydrocortisol [allo-THF] and tetrahydrocortisone [THE]) were measured in 
24-h urine samples. Enzymatic activities of 11β-HSD overall and of 11β-HSD type 2 
were estimated as the urinary (THF + allo-THF [THFs])/THE and cortisol/cortisone 
ratios, respectively. A-ring reductase activity was assessed by ratios of THF/allo-THF, 
allo-THF/cortisol, THF/cortisol and THE/cortisone.
Results: After 24-week, urinary cortisol excretion was decreased in the magnesium 
group as compared with the placebo group (−32 nmol/24-h, 95% CI: −59; −5 nmol/24-
h, p = .021). Ratios of THFs/THE and cortisol/cortisone were decreased following 
magnesium supplementation by 0.09 (95% CI: 0.02; 0.17, p = .018) and 0.10 (95% 
CI: 0.03; 0.17, p = .005), respectively. No effects were observed on A-ring reductase 
activity.
Conclusions: We observed a beneficial effect of magnesium supplementation towards 
a lower 24-h urinary cortisol excretion together with an increased activity of 11β-HSD 
type 2. Our findings may provide another potential mechanism by which increased 
magnesium intake lowers CVD risk (ClinicalTrials.gov identifier: NCT02235805).
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd
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1  |  INTRODUC TION
Low dietary magnesium intake has been associated with increased 
risk of cardiovascular disease (CVD).1 Specifically, we already ob-
served a clinically relevant improvement in arterial stiffness after 
long-term oral magnesium supplementation,2 which may underlie 
the beneficial effects of magnesium on CVD events.
Previous studies have also suggested a role for cortisol in 
CVD risk.3,4 For instance, excess levels of cortisol in patients with 
Cushing's syndrome have been linked to alterations in the vascular 
system, including increased arterial stiffness and impaired endo-
thelial function.5,6 Several enzymes, including 11β-hydroxysteroid 
dehydrogenases (11β-HSDs) and A-ring reductases, regulate in-
tracellular glucocorticoid metabolism and have been suggested 
to play an important role in the pathogenesis of metabolic syn-
drome, which is in turn associated with increased risk of CVD.7-
9 11β-HSDs are primarily responsible for the conversion of inert 
cortisone to active cortisol and vice versa. In fact, two iso-enzymes 
of 11β-HSD have been identified: type 1 and type 2. The former 
is mainly expressed in the liver and adipose tissue and converts 
the inactive cortisone into the active cortisol,10 while the latter is 
primarily expressed in the kidney and colon and is responsible for 
the conversion of cortisol into cortisone.11,12 On the other hand, 
A-ring reductases regulate the conversion of cortisol and cortisone 
to their metabolites tetrahydrocortisol (THF), allo-tetrahydrocor-
tisol (allo-THF) and tetrahydrocortisone (THE). The glucocorticoid 
metabolism is depicted in Figure 1. Enzyme activity of 11β-HSDs 
and A-ring reductases can be quantified by the ratios of 24-h uri-
nary excretions of cortisol, cortisone and their metabolites, which 
provides insight into the intracellular production and clearance of 
cortisol.13,14
Several preclinical studies have shown that magnesium plays a 
role in glucocorticoid metabolism.15-17 In fact, dietary magnesium 
restriction resulted in an altered glucocorticoid metabolism. To date, 
no human intervention trials have addressed effects of oral magne-
sium supplementation on glucocorticoid metabolism.
Here, we performed a post-hoc analysis of a previously per-
formed double-blind placebo-controlled intervention trial with the 
primary aim to study the effect of magnesium supplementation on 
arterial stiffness, measured by carotid-to-femoral pulse wave veloc-
ity. In the current study, we investigated effects of long-term oral 
magnesium supplementation on glucocorticoid metabolism, spe-
cifically on 24-h urinary excretions of cortisol, cortisone and their 
metabolites, as well as on enzyme activity of 11β-HSD and A-ring 
reductases.
2  |  MATERIAL S AND METHODS
2.1  |  Study population
This post-hoc analysis is part of an intervention trial, in which 
healthy overweight and slightly obese men and women received 
either a magnesium citrate supplement or a placebo for 24-week. 
Details of the study characteristics have been described before.2 In 
brief, eligible participants were men and postmenopausal women, 
aged between 45 and 70 years old, and with a body mass index 
(BMI) between 25–35 kg/m2. They had no indications for treatment 
with cholesterol-lowering medications; no active cardiovascular dis-
ease; no active inflammatory disease; no endocrine disorders, such 
as Cushing's syndrome, primary aldosteronism or adrenal inciden-
taloma; and no drug or alcohol abuse. Participants were ineligible for 
participation if they received proton-pump inhibitors, anti-hyper-
tensive medication or drugs known to affect serum lipid or plasma 
glucose metabolism. All study participants gave written consent 
before the screening visit. The study was conducted according to 
the guidelines laid down in the Declaration of Helsinki and was ap-
proved by the Medical Ethics Committee of Maastricht University 
K E Y W O R D S
cardiovascular disease, glucocorticoids, magnesium, metabolism, obesity, randomized 
controlled trial
F I G U R E  1  Schematic overview of glucocorticoid metabolism. 11β-HSD type 1 converts cortisone into cortisol causing increased 
intracellular cortisol levels, while 11β-HSD type 2 decreases intracellular cortisol levels by converting cortisol into cortisone. 5α- and 
5β-reductase enzymes inactivates cortisol and cortisone to their inactive metabolites THF, allo-THF and THE, respectively. 11β-HSD, 
11β-hydroxysteroid dehydrogenase; THF, tetrahydrocortisol; allo; THF, allo-tetrahydrocortisol; THE, tetrahydrocortisone
Cortisol Cortisone
11β-HSD type 2 
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Medical Center. The study was registered at ClinicalTrials.gov as 
NCT02235805.
2.2  |  Study design
The intervention trial had a randomized, double-blind, placebo-con-
trolled, parallel-group design. Study participants were allocated to re-
ceive either a magnesium citrate supplement or a placebo for 24-week 
using a computer-generated randomization scheme stratified by sex. 
The total daily dose of magnesium was 350 mg (Magnesium Citrate 
Complex (Mg 16%). Placebo capsules contained starch (Amylum 
Solani). Capsules were provided in blister strips. Participants were 
requested to return all blisters at the next visit, including any unused 
capsules that were counted as a measure of compliance. Furthermore, 
participants were requested to maintain their usual diet (including 
consumption of alcohol), and their physical activity levels during the 
study period. For the current post-hoc analysis, we used 24-h urine 
samples that were collected at baseline and at the end of the trial.
2.3  |  Measurements
Participants received strict instructions regarding the collection 
of 24-h urine. They discarded the first morning urine samples and 
collected all urine for the following 24-h. A separate container was 
used to collect all urine during the night and the first morning urine 
sample of the next morning after waking. Participants were re-
quested to empty their bladder completely before going to sleep. 
On the day before blood sampling, participants were requested 
not to consume alcohol, nor perform strenuous physical activi-
ties. In addition, participants were requested not to consume any 
foods or drinks (except for water) after 08.00 pm on the day before 
blood sampling. Measurements were performed at the Metabolic 
Research Unit Maastricht (MRUM) research facilities. Fasting 
blood samples were taken from a forearm vein by venipuncture. 
Blood drawn in vacutainer serum tubes (Becton, Dickinson and 
Company) was first allowed to clot for at least 30 min at 21°C. 
Serum separator tubes were then centrifuged at 1300 g for 15 min 
at 21°C. Serum and urine magnesium were determined photo-
metrically with a Magnesium and Calcium Gen.2 assay (COBAS, 
Roche Diagnostics GmbH) by the Central Diagnostic Laboratory 
Maastricht University Medical Center. Cortisol, cortisone, THF, 
allo-THF and THE were measured in 24-h urine samples by iso-
tope dilution liquid chromatography tandem mass spectrometry at 
the University Medical Center Groningen (UMCG), as previously 
described.18 Total production of urinary cortisol, cortisone and 
their metabolites was calculated as the sum of the following me-
tabolites: (urinary cortisol excretion (nmol/24-h)/1000) + (urinary 
cortisone excretion (nmol/24-h)/1000) + urinary THF excretion 
(µmol/24-h) + urinary allo-THF excretion (µmol/24-h) + urinary 
THE excretion (µmol/24-h). Technicians at the MRUM and at the 
UMCG were not aware of the treatments of the participants.
2.4  |  Enzyme activities of 11β-HSDs and 
A-ring reductases
Overall 11β-HSD enzymatic activity was calculated using the ratio 
of urinary metabolites of cortisol and cortisone (THF + allo-THF 
(THFs))/THE.13 The ratio of cortisol/cortisone accurately reflects 
the kidney 11β-HSD type 2 enzyme activity.14 A-ring reductases, 
including 5α- and 5β-reductase, can be inferred by the ratio of THF/
allo-THF (combined 5α- and 5β- reductase activity), allo-THF/corti-
sol (5α-reductase activity), THF/cortisol (5β-reductase activity) and 
THE/cortisone (5β-reductase activity). The ratios are summarized in 
Table 1.
2.5  |  Statistical analyses
The study was powered on the primary endpoint (carotid-to-femoral 
pulse wave velocity) of the intervention trial. A detailed power cal-
culation can be found in our previous paper.2 An intention-to-treat 
analysis (using the last observation carried forward approach) was 
performed. Normality of data was assessed by the Kolmogorov–
Smirnov test. Data are presented as means ± SD or percentages. 
Differences in responses between magnesium and placebo treat-
ments were calculated using a single-factor ANCOVA, with inclusion 
of the baseline measurements of the outcome variable as covariate. 
Sex was considered as a potential confounder and therefore, the 
analyses were adjusted for sex. Changes were calculated as the dif-
ference between the values at the end and the start of the trial. In 
a sensitivity analysis, we performed a single-factor ANCOVA with 
log-transformed data, because the variables 24-h urinary cortisol, 
cortisone and their metabolites as well as the ratios reflecting A-ring 
reductase activity followed a skewed distribution. Skewed data are 
presented as geometric means with 95% confidence intervals. A 
p < .05 was considered statistically significant. We did not adjust for 
TA B L E  1  Summary of ratios
Ratio Index
Cortisol/cortisone 11β-HSD type 2 
activity
THFs/THE 11β-HSD overall 
activity









Abbreviations: 11β-HSD, 11β-hydroxysteroid dehydrogenase; 
THE, tetrahydrocortisone; THFs, tetrahydrocortisol and 
allo-tetrahydrocortisol.
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multiple testing, as the post-hoc analyses we performed are explor-
atory and hypothesis generating. Analyses were performed using 
SPSS version 23.0 for Windows.
3  |  RESULTS
3.1  |  Study population
A total of 51 participants completed the initial intervention trial. 
For the current post-hoc analysis, data on 24-h urinary excre-
tions of cortisol, cortisone and their metabolites were available 
from 49 participants. Baseline characteristics of the 49 partici-
pants that were included in the analysis are presented in Table 2. 
Their mean age was 62 ± 6 years and 22 (44.9%) were female. 
They had an average BMI of 29 ± 3 kg/m2. Baseline measurements 
were comparable between the magnesium and placebo group 
(Table 2). Oral magnesium supplementation led to an increase in 
24-h urinary magnesium excretion, (2.22 mmol/24-h; 95% CI: 1.38; 
3.07 mmol/24-h, p < .001) and a small, but non-significant, increase 
in plasma magnesium (0.01 mmol/L; 95% CI: −0.01; 0.04 mmol/L, 
p = .170) (Table 3). Overall compliance was excellent, as evident by 
the increased 24-h urinary magnesium excretion observed in the 
magnesium group as well as the capsule counts. Compliance, based 
on the returned capsules, ranged from 86% to 102% and was on 
average 99% and 98% for the magnesium group and for the pla-
cebo group, respectively. The magnesium supplements were well 
tolerated. No serious adverse events were observed. Only mild 
headache and mild gastrointestinal complaints were reported for 
7 days by 1 women from the magnesium group (during week 11 of 
the study).
3.2  |  Twenty-four-hour urinary cortisol, 
cortisone and their metabolites
Effects on 24-h urinary excretions of cortisol, cortisone and their 
metabolites are presented in Table 3. After 24-week of magnesium 
supplementation, 24-h urinary cortisol excretion showed a mean 
decrease of 32 nmol/24-h in the magnesium group (95% CI: −59; 
−5 nmol/24-h, p = .021). Mean 24-h urinary THF and allo-THF ex-
cretions were not significantly different between the groups after 
24-week (−0.5 μmol/24-h, 95% CI: −1.2; 0.3 μmol/24-h, p = .231 
and −0.5 μmol/24-h, 95% CI: −1.1; −0.0 μmol/24-h, p = .065, re-
spectively). Oral magnesium supplementation did not change 24-h 
urinary cortisone and THE excretions after 24-week (−1 nmol/24-
h, 95% CI: −38; 35 nmol/24-h, p = .949 and −0.2 μmol/24-h, 95% 
CI: −1.9; 1.6 μmol/24-h, p = .861, respectively). No significant ef-
fect on the total secretion was found (−1.2 μmol/24-h, 95% CI: −4.0; 
1.7 μmol/24-h, p = .420). Additionally, analyses using log-trans-
formed data were performed, but similar effects on cortisol, corti-
sone and their metabolites were observed (Table 4).
3.3  |  Enzyme activity of 11β-HSDs and 
A-ring reductases
Effects of magnesium supplementation on enzymatic activities of 
11β-HSDs and A-ring reductases are shown in Table 3. The corti-
sol/cortisone ratio, which reflects the kidney 11β-HSD type 2 activ-
ity, was lower after 24-week in the magnesium group (−0.10 nmol/
nmol, 95% CI: −0.17; −0.03 nmol/nmol, p = .005) as compared with 
the placebo group. Furthermore, the THFs/THE ratio, which re-
flects the overall measure of 11β-HSD activity, was decreased by 
0.09 μmol/μmol (95% CI: 0.02; 0.17 μmol/μmol, p = .018) following 
magnesium supplementation. No difference in THF/allo-THF ratio, 
as index for 5α- and 5β-reductase activity, was observed between 
the groups. The ratio allo-THF/cortisol, as index for 5α -reductase 
activity, and the ratios THF/cortisol and THE/cortisone reflecting 
5β-reductase activity did also not differ. Finally, no effects of mag-
nesium supplementation on enzyme activities of A-ring reductases 
were found when we performed the analyses with log-transformed 
data (Table 4).
4  |  DISCUSSION
In this post-hoc analysis of a randomized, controlled trial with over-
weight and slightly obese adults, we observed a reduction in 24-h 
urinary cortisol excretion after 24-week of daily supplementation 
with 350 mg magnesium. Also, changes in THFs/THE and cortisol/
cortisone ratios were observed, which reflects an increased kidney 
11β-HSD type 2 activity. These novel findings indicate an increased 
inactivation of cortisol by the 11β-HSD type 2 enzyme that may be 
another potential mechanism by which increased dietary magnesium 
intake lowers CVD risk.






Females, % 48.0 41.7
Age, years 62.6 ± 5.3 61.5 ± 6.1
Body mass index, kg/
m2
29.0 ± 2.5 29.8 ± 3.1
Waist circumference, 
cm
100 ± 9 103 ± 11
Serum triglycerides, 
mmol/L
1.33 ± 0.65 1.37 ± 0.52
Plasma glucose, 
mmol/L
5.52 ± 0.53 5.48 ± 0.61
Serum creatinine, 
µmol/L
79.8 ± 11.5 81.9 ± 13.5
Systolic blood 
pressure, mm Hg
134 ± 14 134 ± 18
Diastolic blood 
pressure, mm Hg
87 ± 8 90 ± 11
Heart rate, beats/min 66 ± 8 68 ± 6
aValues are means ± SDs or percentages. 
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To the best of our knowledge, this is the first human intervention 
trial that addressed the effect of oral magnesium supplementation 
on glucocorticoid metabolism, as assessed by 24-h urinary measure-
ments of cortisol, cortisone and their metabolites. Effects of magne-
sium on glucocorticoid metabolism have been previously reported 
by preclinical studies. A magnesium deficient diet has been shown 
to affect glucocorticoid metabolism in rats.15,16 The latter study 
showed that in rats receiving a magnesium deficient diet, corticoste-
rone concentrations were elevated. Also, the expression of the gene 
encoding the enzyme 11β-HSD type 1 was increased, whereas the 
expression of the gene encoding the enzyme 11β-HSD type 2 was 
decreased. The mechanism underlying the effect of dietary magne-
sium restriction on altered 11β-HSD activity is unknown. Previous 
studies showed that 11β-HSDs are regulated by several cytokines 
and growth factors, including insulin-like growth factor 1 (IGF-1), as 
well as by gonadal steroids.19-21 Interestingly, a magnesium deficient 
diet in rats has been associated with reductions in serum IGF-1.22 
Thus, it might be possible that the potential effects of magnesium 
restriction on IGF-1 underlie the effects on altered 11β-HSD activ-
ity. A limited number of clinical studies observed beneficial effects 
of oral magnesium supplementation on circulating cortisol concen-
trations.23-26 Although evidence regarding the mechanism by which 
magnesium lowers circulating cortisol levels is somewhat controver-
sial, it might be that the effect is mediated by changes in the hypo-
thalamic-pituitary-adrenal (HPA) axis. The HPA axis is an endocrine 
feedback system in which corticotropin-releasing hormone (CRH) 
from the hypothalamus stimulates the anterior pituitary to produce 
adrenocorticotropic hormone (ACTH), while ACTH stimulates the 
adrenal cortex to produce cortisol. Indeed, a previous study in mice 
showed deregulation of the HPA axis induced by a magnesium defi-
cient diet, as evident by an increased transcription of the CRH and 
increased plasma CRH concentrations.27 Another study conducted 
in healthy men found that after magnesium administration, secretion 
of ACTH was significantly reduced.28
Glucocorticoids are essential for maintenance of vascular tone. 
Findings from (pre)clinical studies have shown that 11β-HSDs are 
TA B L E  3  Magnesium and cortisol and cortisone measurements at baseline and after a 24-week magnesium or placebo treatment
Magnesium group (n = 25) Placebo group (n = 24) Treatment effect




Serum magnesium, mmol/L 0.85 ± 0.05 0.87 ± 0.04 0.85 ± 0.05 0.85 ± 0.05 0.01 (−0.01; 0.04) .170
Urinary magnesium, 
mmol/24-h
4.70 ± 1.16 6.46 ± 1.16 4.30 ± 1.46 4.24 ± 2.10 2.22 (1.38; 3.07) <.001
24-h urinary cortisol and cortisone excretions
Cortisol, nmol/24-h 204 ± 64 188 ± 46 226 ± 110 220 ± 88 −32 (−59; −5) .021
THF, μmol/24-h 5.5 ± 1.8 4.7 ± 1.3 5.2 ± 2.4 5.1 ± 2.0 −0.5 (−1.2; 0.3) .231
allo-THF, μmol/24-h 3.2 ± 1.9 2.9 ± 1.6 3.3 ± 1.9 3.4 ± 2.1 −0.5 (−1.1; −0.0) .065
Cortisone, nmol/24-h 272 ± 91 271 ± 83 285 ± 112 272 ± 102 −1 (−38; 35) .949
THE, μmol/24-h 10.2 ± 4.1 9.7 ± 3.9 9.9 ± 4.3 9.8 ± 4.7 −0.2 (−1.9; 1.6) .861
Total production, 
μmol/24-h




0.78 ± 0.17 0.71 ± 0.15 0.80 ± 0.17 0.82 ± 0.15 −0.10 (−0.17; −0.03) .005
THFs/THE, μmol/μmol 0.90 ± 0.27 0.84 ± 0.22 0.94 ± 0.32 0.93 ± 0.32 −0.09 (−0.17; −0.02) .018
Index for A-ring reductases
THF/allo-THF, μmol/μmol 4.1 ± 9.1 3.5 ± 5.9 4.2 ± 12.4 3.7 ± 9.8 −0.21 (−0.80; 0.38) .280
allo-THF/cortisol, μmol/
μmol
15.8 ± 8.3 16.0 ± 8.8 16.2 ± 7.1 15.0 ± 6.7 1.00 (−1.22; 3.21) .371
THF/cortisol, μmol/μmol 28.1 ± 8.0 25.7 ± 6.5 24.8 ± 10.1 24.2 ± 7.0 1.48 (−0.91; 3.87) .204
THE/cortisone, μmol/μmol 39.5 ± 14.3 37.0 ± 15.5 36.0 ± 12.7 37.9 ± 15.9 −0.8 (−7.0 5.3) .781
Urine volume, ml 1377 ± 505 1480 ± 517 1565 ± 486 1269 ± 481 212 (−0; 423) .050
Abbreviations: 11β-HSDs, 11β-hydroxysteroid dehydrogenases; allo-THF, allo-tetrahydrocortisol; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
aValues are means ± SDs. 
bValues are adjusted mean estimates (95% Confidence Intervals) obtained from a one-way ANCOVA with baseline value of the dependent variable as 
covariate. 
cModels were additionally adjusted for sex. 
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expressed in the vascular wall, presumably in vascular smooth 
muscle cells.29,30 In fact, a study of Hadoke et al have demon-
strated that mice with 11β-HSD type 2 knock-out developed en-
dothelial dysfunction.31 The authors concluded that 11β-HSD type 
2, rather than 11β-HSD type 1, influences vascular tone in mice. 
Thus, targeting this enzyme likely reduce cortisol action and may 
contribute to a lower CVD risk.10 Indeed, patients with Cushing's 
syndrome show an increased risk of the metabolic syndrome,32 
which is in turn associated with increased risk of CVD.9 Alterations 
in the vascular system may underlie these associations. Baykan 
et al showed that endothelial function in patients with Cushing's 
syndrome was impaired.6 Another study observed increased ar-
terial stiffness in these patients, which was independent of blood 
pressure elevation.33
Emerging evidence suggests that increasing dietary magnesium 
intake could be an important dietary approach to reduce the risk of 
CVD.1 Indeed, we previously showed a clinically relevant improve-
ment on arterial stiffness, measured with carotid-to-femoral pulse 
wave velocity, after long-term magnesium supplementation.2 In 
the current study, we found that oral magnesium supplementation 
significantly increased 11β-HSD type 2 activity in overweight and 
slightly obese adults, which may provide a mechanistic link between 
dietary magnesium intake and cardiovascular health benefits.
It is well known that glucocorticoids contribute to insulin resis-
tance.34 Interestingly, accumulating evidence suggest a beneficial 
role of magnesium in insulin sensitivity.35 Thus, it might be possible 
that magnesium improves glucocorticoid metabolism, thereby af-
fecting insulin sensitivity, which in turn reduces the risk of CVD. It 
should be noted that in our previous study, we did not observe an ef-
fect of oral magnesium supplementation on insulin sensitivity.36 The 
lack of effect could be explained by the fact that the participants had 
baseline serum magnesium levels within the normal range. In fact, 
subgroup analyses of a meta-analysis that summarized the effects of 
oral magnesium supplementation on fasting glucose, insulin and the 
HOMA-IR index revealed that greater reductions of the HOMA-IR 
index were found in subjects with hypomagnesaemia at baseline.37
Major strengths of the present study include the double-blinded 
placebo-controlled design, as well as the long duration of the inter-
vention trial. Another strength includes the use of 24-h urinary corti-
sol and cortisone excretion and measurements of their metabolites, 
which allowed us to study underlying mechanisms. Specifically, the 
enzyme activity of intracellular 11β-HSDs and A-ring reductases can 
be quantified from 24-h urine concentrations of cortisol, cortisone 
and their metabolites. This approach provides important insight into 
the intracellular regulation of glucocorticoids.
A potential limitation of our study is that we were not able 
to define effects of oral magnesium supplementation on the 11β-
HSD type 1 activity. The 11β-HSD type 1 activity can only be 
inferred from the THFs/THE ratio when the cortisol/cortisone 
ratios is unchanged.14 In the current study, the cortisol/cortisone 
TA B L E  4  Cortisol and cortisone measurements at baseline and after a 24-week magnesium or placebo treatment (sensitivity analysis)
Magnesium group (n = 25) Placebo group (n = 24) Treatment effect
Baselinea  24 weeksa  Baselinea  24 weeksa 
Adjusted effect 
stimateb,c  p-value
24-h urinary cortisol and cortisone excretion
Log cortisol, nmol/24-h 195 (171; 221) 179 (164; 196) 204 (172; 241) 206 (188; 225) 0.87 (0.77; 0.99) .032
Log THF, μmol/24-h 5.3 (4.7; 6.0) 4.5 (4.0; 5.0) 4.7 (3.9; 5.7) 4.8 (4.3; 5.3) 0.93 (0.79; 1.10) .394
Log allo-THF, μmol/24-h 2.4 (1.7; 3.4) 2.3 (2.1; 2.6) 2.7 (1.9; 3.6) 2.5 (2.2; 2.8) 0.92 (0.78; 1.09) .351
Log cortisone, 
nmol/24-h
256 (221; 291) 256 (233; 282) 261 (217; 309) 256 (233; 282) 1.00 (0.87; 1.16) .985
Log THE, μmol/24-h 9.5 (8.1; 10.9) 8.9 (7.9; 10.0) 8.8 (7.2; 10.9) 8.8 (7.8; 9.9) 1.01 (0.86; 1.19) .915
Log total production, 
μmol/24-h
18.4 (16.1; 20.9) 16.6 (15.0; 18.6) 17.4 (14.7; 20.7) 17.3 (15.5; 19.2) 0.97 (0.83; 1.13) .669
Index for A-ring reductases
Log THF/allo-THF, 
μmol/μmol
2.1 (1.5; 2.9) 1.9 (1.7; 2.1) 1.8 (1.4; 2.6) 1.9 (1.8; 2.1) 0.96 (0.85; 1.09) .572
Log allo-THF/cortisol, 
μmol/μmol
12.5 (8.9; 16.7) 12.9 (11.7; 14.2) 12.6 (8.5; 16.6) 12.2 (11.1; 13.5) 1.05 (0.91; 1.21) .471
Log THF/cortisol, μmol/
μmol
25.9 (23.5; 28.4) 24.7 (22.9; 26.5) 22.2 (19.7; 25.1) 23.4 (21.7; 25.2) 1.05 (0.95; 1.17) .317
Log THE/cortisone, 
μmol/μmol
35.9 (31.1; 41.4) 34.6 (31.1; 38.4) 33.2 (28.3; 39.4) 34.6 (31.0; 38.5) 1.00 (0.86; 1.16) .999
Abbreviations: allo-THF, allo-tetrahydrocortisol; THE, tetrahydrocortisone; THF, tetrahydrocortisol.
aValues are geometric means (95% CIs). 
bValues are geometric mean ratios (95% CIs) obtained from a one-way ANCOVA with baseline value of the dependent variable as covariate. 
cModels were additionally adjusted for sex. All variables were log-transformed before entering the model. 
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ratio was changed after the treatment period in the magnesium 
group, which may imply an effect on whole-body 11β-HSD activ-
ity, rather than an effect on the specific 11β-HSD type 1 activity. 
Second, licorice-derivatives, such as glycyrrhizic acid, inhibit the 
enzymatic activity of 11β-HSD type 2. Whether the intake of lic-
orice has influenced our results, is not entirely clear, because no 
data on licorice intake were available. However, participants were 
requested not to change their dietary intake pattern during the 
study. Results from the food frequency questionnaires showed in-
deed that dietary intake (macro and micro-nutrient intake) did not 
change during the study, suggesting that it is unlikely that licorice 
intake affected our results.2 Furthermore, we could not differen-
tiate whether the effect on glucocorticoid metabolism was due 
to supplementation of magnesium or due to potential effects of 
citrate. However, in our future study, we will address effects of 
different magnesium supplements (magnesium citrate, magnesium 
oxide and magnesium sulphate) on cardiovascular risk markers, 
including arterial stiffness and blood pressure.38 Finally, as the 
post-hoc analyses we performed are exploratory and hypoth-
esis generating, the current findings should be interpreted with 
caution.
To conclude, we observed a beneficial effect of oral magne-
sium supplementation towards a lower 24-h urinary cortisol ex-
cretion together with an increased activity of 11β-HSD type 2. 
Our findings may indicate improved glucocorticoid metabolism in-
duced by oral magnesium supplementation, suggesting a potential 
mechanism by which increased dietary magnesium intake lowers 
CVD risk. Our results provide a basis to further investigate effects 
of oral magnesium supplementation on CVD risk and underlying 
mechanisms.
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